Taysha Gene Therapies, Inc. (TSHA)

NASDAQ: TSHA · IEX Real-Time Price · USD

2.140

-0.120 (-5.31%)

At close: Jul 19, 2024, 4:00 PM

2.250

+0.110 (5.14%)

Pre-market: Jul 22, 2024, 9:03 AM EDT

Taysha Gene Therapies Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	431	331	141	448	1,002
Market Cap Growth	960.20%	134.50%	-68.52%	-55.28%	-
Enterprise Value	363	244	109	334	751
PE Ratio	-	-2.97	-0.85	-2.57	-16.70
PS Ratio	30.44	21.42	56.40	-	-
PB Ratio	8.00	4.42	148.70	4.70	3.99
P/FCF Ratio	-7.38	-4.30	-1.29	-3.39	-32.53
P/OCF Ratio	-7.39	-4.53	-1.60	-3.83	-32.61
EV/Sales Ratio	25.67	15.78	43.57	-	-
EV/EBITDA Ratio	-4.20	-2.34	-0.68	-1.93	-12.52
EV/EBIT Ratio	-4.10	-2.29	-0.67	-1.93	-12.52
EV/FCF Ratio	-6.45	-3.17	-1.00	-2.52	-24.37
Debt / Equity Ratio	1.10	0.79	61.55	0.39	-
Debt / EBITDA Ratio	-0.53	-0.57	-0.37	-0.22	-
Debt / FCF Ratio	-0.81	-0.77	-0.54	-0.28	-
Quick Ratio	3.28	3.99	1.44	2.93	35.24
Current Ratio	3.38	4.08	1.54	3.08	36.17
Asset Turnover	0.09	0.11	0.02	0	0
Interest Coverage	-31.30	-21.32	-42.71	-121.21	-2142.25
Return on Equity (ROE)	-1109.10%	1700.80%	-695.30%	-108.20%	-47.80%
Return on Assets (ROA)	-78.30%	-80.90%	-121.60%	-74.30%	-46.40%
Return on Capital (ROIC)	-71.07%	-53.90%	-273.68%	-130.69%	-17.11%
Earnings Yield	-27.38%	-33.71%	-117.64%	-38.94%	-5.99%
FCF Yield	-16.88%	-23.23%	-77.25%	-29.53%	-3.07%
Buyback Yield / Dilution	-265.55%	-164.20%	-16.74%	-113.13%	-
Total Shareholder Return	-265.55%	-164.20%	-16.74%	-113.13%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).